KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Non Operating Income (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Non Operating Income for 15 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 59.35% to $2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.3 million through Dec 2025, down 18.21% year-over-year, with the annual reading at $13.3 million for FY2025, 18.21% down from the prior year.
  • Non Operating Income for Q4 2025 was $2.0 million at Supernus Pharmaceuticals, down from $2.3 million in the prior quarter.
  • The five-year high for Non Operating Income was $14.7 million in Q1 2022, with the low at -$21.5 million in Q4 2021.
  • Average Non Operating Income over 5 years is $2.2 million, with a median of $2.4 million recorded in 2021.
  • The sharpest move saw Non Operating Income plummeted 551.62% in 2021, then surged 711.52% in 2024.
  • Over 5 years, Non Operating Income stood at -$21.5 million in 2021, then skyrocketed by 103.74% to $806000.0 in 2022, then skyrocketed by 146.4% to $2.0 million in 2023, then skyrocketed by 150.6% to $5.0 million in 2024, then tumbled by 59.35% to $2.0 million in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at $2.0 million, $2.3 million, and $4.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.